160 related articles for article (PubMed ID: 22101282)
1. Targeted diazeniumdiolates: localized nitric oxide release from glioma-specific peptides and proteins.
Safdar S; Taite LJ
Int J Pharm; 2012 Jan; 422(1-2):264-70. PubMed ID: 22101282
[TBL] [Abstract][Full Text] [Related]
2. A glycosylated nitric oxide donor, beta-Gal-NONOate, and its site-specific antitumor activity.
Chen C; Shi Y; Li S; Qi Q; Gu L; Song J; Wang PG
Arch Pharm (Weinheim); 2006 Jul; 339(7):366-71. PubMed ID: 16783837
[TBL] [Abstract][Full Text] [Related]
3. Nitroreductase-activated nitric oxide (NO) prodrugs.
Sharma K; Sengupta K; Chakrapani H
Bioorg Med Chem Lett; 2013 Nov; 23(21):5964-7. PubMed ID: 24050886
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro.
Weyerbrock A; Baumer B; Papazoglou A
J Neurosurg; 2009 Jan; 110(1):128-36. PubMed ID: 18991497
[TBL] [Abstract][Full Text] [Related]
5. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
6. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
Pulkkinen M; Pikkarainen J; Wirth T; Tarvainen T; Haapa-aho V; Korhonen H; Seppälä J; Järvinen K
Eur J Pharm Biopharm; 2008 Sep; 70(1):66-74. PubMed ID: 18555675
[TBL] [Abstract][Full Text] [Related]
7. Novel α-ketoamide based diazeniumdiolates as hydrogen peroxide responsive nitric oxide donors with anti-lung cancer activity.
Fu J; Han J; Meng T; Hu J; Yin J
Chem Commun (Camb); 2019 Oct; 55(86):12904-12907. PubMed ID: 31584577
[TBL] [Abstract][Full Text] [Related]
8. Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors.
Yin D; Wang X; Konda BM; Ong JM; Hu J; Sacapano MR; Ko MK; Espinoza AJ; Irvin DK; Shu Y; Black KL
Clin Cancer Res; 2008 Jun; 14(12):4002-9. PubMed ID: 18559623
[TBL] [Abstract][Full Text] [Related]
9. Use of chlorotoxin for targeting of primary brain tumors.
Soroceanu L; Gillespie Y; Khazaeli MB; Sontheimer H
Cancer Res; 1998 Nov; 58(21):4871-9. PubMed ID: 9809993
[TBL] [Abstract][Full Text] [Related]
10. Permeability changes in response to NONOate and NONOate prodrug derived nitric oxide in a blood-brain barrier model formed by primary porcine endothelial cells.
Winter S; Konter J; Scheler S; Lehmann J; Fahr A
Nitric Oxide; 2008 May; 18(3):229-39. PubMed ID: 18284923
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide donors attenuate clongenic potential in rat C6 glioma cells treated with alkylating chemotherapeutic agents.
Yang JJ; Yin JH; Yang DI
Neurosci Lett; 2007 May; 418(1):106-10. PubMed ID: 17412510
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of β-galactosyl-pyrrolidinyl diazeniumdiolate with cisplatin against three tumor cells.
Deng L; Zhang E; Chen C
Arch Pharm Res; 2013 May; 36(5):619-25. PubMed ID: 23494564
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration.
Huang R; Ke W; Han L; Li J; Liu S; Jiang C
Biomaterials; 2011 Mar; 32(9):2399-406. PubMed ID: 21185076
[TBL] [Abstract][Full Text] [Related]
14. Sialated diazeniumdiolate: a new sialidase-activated nitric oxide donor.
Cai TB; Lu D; Landerholm M; Wang PG
Org Lett; 2004 Nov; 6(23):4203-5. PubMed ID: 15524443
[TBL] [Abstract][Full Text] [Related]
15. Chlorotoxin-conjugated nanoparticles for targeted imaging and therapy of glioma.
Zhao L; Shi X; Zhao J
Curr Top Med Chem; 2015; 15(13):1196-208. PubMed ID: 25858130
[TBL] [Abstract][Full Text] [Related]
16. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
17. More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings.
Batchelor MM; Reoma SL; Fleser PS; Nuthakki VK; Callahan RE; Shanley CJ; Politis JK; Elmore J; Merz SI; Meyerhoff ME
J Med Chem; 2003 Nov; 46(24):5153-61. PubMed ID: 14613318
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of human glioblastoma cell lines differently resistant to a nitric oxide releasing agent.
Leone R; Giussani P; De Palma S; Fania C; Capitanio D; Vasso M; Brioschi L; Riboni L; Viani P; Gelfi C
Mol Biosyst; 2015 Jun; 11(6):1612-21. PubMed ID: 25797839
[TBL] [Abstract][Full Text] [Related]
19. Novel primary amine diazeniumdiolates-Chemical and biological characterization.
Puglisi MP; Bradaric MJ; Pontikis J; Cabai J; Weyna T; Tednes P; Schretzman R; Rickert K; Cao Z; Andrei D
Drug Dev Res; 2018 May; 79(3):136-143. PubMed ID: 29719056
[TBL] [Abstract][Full Text] [Related]
20. Targeting autophagy enhances BO-1051-induced apoptosis in human malignant glioma cells.
Chu PM; Chen LH; Chen MT; Ma HI; Su TL; Hsieh PC; Chien CS; Jiang BH; Chen YC; Lin YH; Shih YH; Tu PH; Chiou SH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):621-33. PubMed ID: 21947203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
